• Text Sizes
  • Site Map
  • Privacy Policy
  • Legal Notice


e-mail this page

News Center


Welcome to the McNeil Pediatrics™ News Center. Here you'll find our latest press releases and corporate statements.

 

Press Releases


Following are recent news releases issued by McNeil Pediatrics™.

11/04/2009 CONCERTA®(methylphenidate HCI) in the Classroom: New Data on Attention in Children with ADHD
09/09/2009 CONCERTA®(methylphenidate HCI) Launches Mobile Web Experience To Provide Tools and Support for ADHD Awareness
09/18/2008 ADHD Awareness Week
07/09/2008 ADHD Moms™ Facebook Launch
06/27/2008 CONCERTA®(methylphenidate HCl) Adult Indication Press Release
05/07/2008 OROS® Methylphenidate in Adults with ADHD: New Insights
10/26/2007 New Study of CONCERTA® Showed Significant Improvement Of ADHD Symptom Management in Adults Compared to Placebo
05/23/2007 New Data Suggests Less Abuse-Related Effects For OROS® Methylphenidate
10/26/2006 New Study Supports Low Abuse Potential of Leading ADHD Medication, CONCERTA® (methylphenidate HCl)
07/17/2006 McNeil Pediatrics Presents Data on CONCERTA® (methylphenidate HCl) Formulation

 

Corporate Statements


Check here for updates on any McNeil Pediatrics™ statements. There are no statements at this time.

Media Contact:
Tricia Geoghegan
E-Mail: tgeogheg@its.jnj.com
Phone: (609)730-3746





CONCERTA® is a prescription product approved for the treatment of attention deficit hyperactivity disorder (ADHD) as part of a total treatment program that may include counseling or other therapies.

IMPORTANT SAFETY INFORMATION


Talk to your healthcare professional for a proper diagnosis and treatment of ADHD. Only a healthcare professional can decide whether medication is right for you or your child.

CONCERTA® should not be taken by patients who have: allergies to methylphenidate or other ingredients in CONCERTA®; significant anxiety, tension, or agitation; glaucoma; tics, Tourette's syndrome, or family history of Tourette's syndrome; current or past use of monoamine oxidase inhibitor (MAOI); esophagus, stomach, or intestinal narrowing. Children under six years of age should not take CONCERTA®.

Abuse of methylphenidate may lead to dependence. Tell your healthcare professional if you or your child has had problems with alcohol or drugs; has had any heart problems, heart defects, high blood pressure, or a family history of these problems; has had depression, abnormal thoughts or visions, bipolar disorder, or seizure. Contact your healthcare professional immediately if you or your child: develops abnormal thinking or hallucinations, abnormal or extreme moods and/or excessive activity; or if aggressive behavior or hostility develops or worsens while taking CONCERTA®. Your child's healthcare professional should check height and weight often and may interrupt CONCERTA® treatment if your child is not growing or gaining weight as expected.

Stimulants may impair the ability of the patient to operate potentially hazardous machinery or vehicles. Caution should be used accordingly until you are reasonably certain that CONCERTA® does not adversely affect your ability to engage in such activities.

The most common adverse reaction (>5%) reported in children and adolescents was upper abdominal pain. The most common adverse reactions (>10%) reported in adults were dry mouth, nausea, decreased appetite, headache, and insomnia.

See full U.S. Prescribing Information and Medication Guide for CONCERTA®.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Footer Close